Marksans Pharma Limited has informed the Exchange regarding a press release dated Jun 19, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary in the UK, Relonchem Limited receives Marketing Authorization for the product Oxybutynin hydrochloride 2.5mg/5ml Oral Solution.".